Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7379
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,195.03
    +735.40 (+0.78%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    +0.23 (+1.80%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,386.97
    +218.90 (+0.54%)
     
  • CAD/EUR

    0.6845
    +0.0002 (+0.03%)
     

Company News for Jan 31, 2020

  • Shares of Miragen Therapeutics, Inc. MGEN surged 20.7% after the company reported positive data from its continuing Phase 1 trial of cobomarsen in adult t-cell leukemia/lymphoma patients with residual disease.

  • Shares of Inovio Pharmaceuticals, Inc. INO gained 13.4% after the company announced collaboration with Beijing Advaccine Biotechnology for advancement of INO-4800 against the Coronavirus.

  • Shares of Mondelez International, Inc. MDLZ rose 7.8% after the company reported quarterly earnings of 61 cents per share, which beat the Zacks Consensus Estimate by a penny.

  • Shares of Briggs & Stratton Corporation BGG declined 21% after the company reported a quarterly loss of $0.20 per share against the Zacks Consensus Estimate of a loss of $0.11.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Mondelez International, Inc. (MDLZ) : Free Stock Analysis Report
 
Briggs & Stratton Corporation (BGG) : Free Stock Analysis Report
 
Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report
 
Signal Genetics, Inc. (MGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research